Asthma

The National Institute for Health and Care Excellence (NICE) has issued a Final Appraisal Determination (FAD) recommending Dupixent® (dupilumab), as an add-on maintenance treatment for severe asthma.[1*] The NICE FAD is based on a subset of patients taking part in the LIBERTY ASTHMA QUEST clinical trial. Dupilumab acts on the type 2 immune response which […]

Before using Apo-Prednisone Tablet, inform your doctor about your current list of medications, over the counter products (e.g. vitamins, herbal supplements, etc.), allergies, pre-existing diseases, and current health conditions (e.g. pregnancy, upcoming surgery, etc.). Some health conditions may make you more susceptible to the side-effects of the drug. Take as directed by your doctor or […]

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. […]

Background No consensus exists on how to reduce oral corticosteroids after the initiation of biologics in severe asthma. The PONENTE trial evaluated the effectiveness and safety of a rapid, individualised steroid-reduction algorithm, including adrenal insufficiency monitoring, after benralizumab initiation. Methods This multicentre, open-label, single-arm study was done at 138 clinical asthma treatment centres across 17 […]

A once-a-day, high-dose combination mometasone furoate/indacaterol acetate (MF/IND) reduced asthma exacerbations and improved lung function to a greater degree than twice a day, high-dose fluticasone propionate/salmeterol xinafoate (FLU/SAL), according to the results of a recent study published in BMJ Open Respiratory Research. Researchers examined the pooled results from the PALLADIUM (ClinicalTrials.gov Identifier: NCT02554786) and IRIDIUM […]

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.   ClinicalTrials.gov Identifier: NCT03414177 Recruitment Status : Completed First Posted : January 29, 2018 Last Update Posted : […]

New data from the phase 3 of the LIBERTY VOYAGE ASTHMA study confirmed that the monoclonal antibody dupilumab caused significant reductions in the exacerbation rate and improvements in lung function and asthma control in pediatric patients with moderate-to-severe asthma The findings were presented last week at the European Respiratory Society 2021 International Congress. Leading investigator […]

Patients with severe asthma and the subspecialists who treat them have varying perceptions of disease control and treatment effectiveness. This was among the findings of the CHRONICLE study (ClinicalTrials.gov identifier: NCT03373045) that were recently published in the Journal of Asthma. CHRONICLE, a large, ongoing, observational study of patients with severe asthma and their treating subspecialists […]

Asthma education is essential in improving outcomes in asthma management. Patients with asthma exacerbation frequently present to the urgent care centre or emergency department for emergency treatment. Nurse-led asthma education was considered as beneficial to asthma management. However, not all nursing staff in the urgent care centre and emergency department are equipped with skills to […]